|ARCA biopharma Announces Changes to Management Team|
|By Staff and Wire Reports|
|Wednesday, 01 July 2009 15:52|
“Today ARCA must balance its cash resources with the continued prosecution of the Gencaro New Drug Application,” said Richard B. Brewer, incoming Chairman of the Board of Directors. “These changes in management focus are intended to allow exactly that to happen, while advancing the strategic interests of the stockholders.”
“I look forward to Dick’s continued contributions to ARCA as Chairman of our Board of Directors,” said Michael R. Bristow, incoming President and Chief Executive Officer of ARCA. “His experience and expertise with cardiovascular therapeutics and the biotechnology industry in general will be a great asset to the Company as we continue seeking regulatory approval of Gencaro.”
About ARCA biopharma
ARCA biopharma, Inc. is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, was filed in September 2008. On May 29, 2009, ARCA received a Complete Response letter from the FDA. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit www.arcabiopharma.com.